论文部分内容阅读
目的比较左西孟旦与多巴酚丁胺治疗急性冠脉综合征并心力衰竭的临床疗效。方法选取2015年某院收治的急性冠脉综合征并心力衰竭患者100例,随机分为研究组与对照组,各50例。研究组予以左西孟旦治疗,对照组予以多巴酚丁胺治疗。比较两组患者治疗前后左室射血分数、左室舒张末期内径及动脉血氧分压、二氧化碳分压及氧饱和度,临床疗效、不良反应发生情况。结果治疗前两组患者左室射血分数、左室舒张末期内径及动脉血氧分压、二氧化碳分压及氧饱和度比较,差异无统计学意义(P>0.05);治疗后两组患者左室射血分数、左室舒张末期内径及动脉血氧分压、二氧化碳分压及氧饱和度比较,差异有统计学意义(P<0.05)。研究组总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者不良发应发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦治疗急性冠脉综合征并心力衰竭的疗效优于多巴酚丁胺,可有效改善患者临床症状,且不良反应少。
Objective To compare the clinical efficacy of levosimendan with dobutamine in the treatment of acute coronary syndrome and heart failure. Methods A total of 100 patients with acute coronary syndrome and heart failure admitted to a hospital in 2015 were randomly divided into study group and control group, 50 cases in each group. The study group was treated with levosimendan and the control group with dobutamine. The left ventricular ejection fraction, left ventricular end-diastolic diameter and arterial partial pressure of oxygen, carbon dioxide partial pressure and oxygen saturation, clinical efficacy and adverse reactions were compared between the two groups before and after treatment. Results There was no significant difference in left ventricular ejection fraction, left ventricular end-diastolic diameter and arterial partial pressure of oxygen, carbon dioxide partial pressure and oxygen saturation between the two groups before treatment (P> 0.05). After treatment, left The ejection fraction, left ventricular end-diastolic diameter and arterial partial pressure of oxygen, carbon dioxide partial pressure and oxygen saturation, the difference was statistically significant (P <0.05). The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P <0.05). There was no significant difference between the two groups in incidence of bad hair (P> 0.05). Conclusion The efficacy of levosimendan in the treatment of acute coronary syndrome and heart failure is superior to dobutamine, which can effectively improve the clinical symptoms of patients with less adverse reactions.